Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + ivonescimab + pemetrexed
- Development stage
- Unknown
- Lead developer
- Summit Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of ivonescimab (a bispecific antibody targeting PD-1 and VEGF-A) plus the chemotherapy agents pemetrexed and carboplatin. The regimen works through multiple mechanisms: ivonescimab simultaneously blocks PD-1/PD-L1 interaction (relieving immunosuppression) and VEGF-A/VEGFR2 binding (inhibiting tumor angiogenesis), while pemetrexed inhibits multiple folate-dependent enzymes involved in DNA synthesis and folate metabolism, and carboplatin forms DNA adducts that disrupt cellular replication. This combination received approval in China in May 2024 for EGFR-mutated locally advanced or metastatic non-squamous NSCLC in patients who have progressed after tyrosine kinase inhibitor therapy.
- Other names
- ivonescimab + pemetrexed + carboplatin
02
Targets
GART (GAR transformylase)DNADHFR (Dihydrofolate reductase)VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on carboplatin + ivonescimab + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + ivonescimab + pemetrexed.